2022
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial
Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022, 163: 608-619. PMID: 35679950, DOI: 10.1053/j.gastro.2022.05.055.Peer-Reviewed Original ResearchConceptsEradication rateHelicobacter pylori infectionTriple therapyDual therapyPylori infectionProton pump inhibitor-based triple therapyTreatment-emergent adverse eventsInhibitor-based triple therapyPotassium-competitive acid blockerEfficacy of vonoprazanH pylori eradicationPhase 3 trialOverall study populationAmoxicillin-resistant strainsClarithromycin-resistant strainsH pylori infectionTreatment-naïve adultsPylori eradicationAdverse eventsSecondary outcomesPrimary outcomeStandard treatmentClinical trialsStudy populationAcid blocker
2003
Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial
Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North American Trial. The American Journal Of Gastroenterology 2003, 98: ajg2003137. PMID: 12650788, DOI: 10.1111/j.1572-0241.2003.t01-1-07288.x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAmoxicillinAnti-Bacterial AgentsAnti-Ulcer AgentsCapsulesDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationDuodenal UlcerFemaleHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMiddle AgedNorth AmericaOmeprazoleOrganometallic CompoundsTetracyclineTreatment OutcomeConceptsUrea breath testQuadruple therapyDuodenal ulcerBreath testNegative urea breath testTreat eradication ratesH. pylori eradicationActive duodenal ulcerDuodenal ulcer patientsNorth American trialsClarithromycin-resistant strainsActive-controlled trialHelicobacter pylori infectionTreatment of patientsMetronidazole-resistant strainsCapsules q.OAC patientsOAC regimenEradication ratePylori eradicationTriple therapyAdverse eventsUlcer patientsPylori infectionMetronidazole resistanceIs it time for quadruple therapy to be first line?
Laine L. Is it time for quadruple therapy to be first line? 2003, 347-351. DOI: 10.1007/978-94-017-1763-2_36.ChaptersProton pump inhibitorsTriple therapyEradication ratePylori infectionCombination of PPIBismuth-based triple therapyPooled eradication ratesH. pylori infectionHelicobacter pylori infectionQuadruple therapyEarly therapyCurrent therapiesPump inhibitorsSeparate medicationsTherapyFirst lineInfectionStudies2–4Medications
2000
How to explain outcome differences in dyspepsia studies
Fennerty M, Laine L. How to explain outcome differences in dyspepsia studies. 2000, 421-425. DOI: 10.1007/978-94-011-3927-4_44.ChaptersNon-ulcer dyspepsiaPylori infectionAdequate observation periodPlacebo-controlled trialPeptic ulcer diseaseCause of symptomsH. pylori infectionHelicobacter pylori infectionClinical treatment trialsMajor aetiological factorUlcer diseaseTreatment trialsUpper abdomenAetiological factorsEarly trial resultsStudy populationOutcome differencesEpidemiological studiesH. pyloriDyspepsiaDiscordant resultsTrial resultsObservation periodSerious methodological deficienciesTrials
1999
Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing?
Faigel D, Vartan G, Knigge K, Laine L, Fennerty M, Margaret N, Marquis S. Fingerstick Helicobacter pylori antibody test: better than laboratory serological testing? The American Journal Of Gastroenterology 1999, 94: ajg1999810. PMID: 10606304, DOI: 10.1111/j.1572-0241.1999.01510.x.Peer-Reviewed Original ResearchReview article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment
Schoenfeld, Kimmey, Scheiman, Bjorkman, Laine. Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment. Alimentary Pharmacology & Therapeutics 1999, 13: 1273-1285. PMID: 10540041, DOI: 10.1046/j.1365-2036.1999.00617.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsPylori infectionSerious gastrointestinal complicationsH. pylori infectionHelicobacter pylori infectionProton pump inhibitorsLowest possible dosagePotential of treatmentNSAID therapyNSAID useAnalgesic therapyCorticosteroid useGastrointestinal bleedingUlcer diseaseAntisecretory agentsPump inhibitorsChronic ingestionPain relieversNSAIDsComplicationsPatientsExact associationPossible dosageRoutine testingPast historyOnce-daily therapy for H. pylori infection: a randomized comparison of four regimens
Laine L, Estrada R, Trujillo M, Cheybani K, Yeramian P, Smith S, Neil G. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. The American Journal Of Gastroenterology 1999, 94: 962. PMID: 10201465, DOI: 10.1111/j.1572-0241.1999.995_r.x.Peer-Reviewed Original ResearchConceptsH. pylori infectionEradication ratePylori infectionExtended-release formulationDaily therapyBreath testDaily triple therapyHigh-dose omeprazoleTreat eradication ratesCompletion of therapyHelicobacter pylori infectionRepeat breath testStudy medicationTriple therapyEndoscopic biopsyRandomized comparisonLack of complianceTherapyPilot studyInfectionFurther studiesClarithromycinOmamDaysSubjects
1998
Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection
Sadowski D, Cohen H, Laine L, Greenberg P, Goldstein J, Mihalov M, Cutler A. Evaluation of the FlexSure HP whole blood antibody test for diagnosis of Helicobacter pylori infection. The American Journal Of Gastroenterology 1998, 93: ajg1998490. PMID: 9820383, DOI: 10.1111/j.1572-0241.1998.00604.x.Peer-Reviewed Original ResearchConceptsHelicobacter pylori infectionRapid urease testPylori infectionWhole blood testH. pyloriWhole bloodBlood testsUrease testPositive rapid urease testBlood antibody testH. pylori infectionProton pump inhibitorsH. pylori diagnosisDetection of antibodiesUpper endoscopyStudy enrollmentPump inhibitorsGastric biopsiesIgG antibodiesSerum testAntibody testOffice testsAntral tissueBacterial infectionsPatientsAn office-based whole blood test is preferable to a laboratory quantitative serology test in the determination of Helicobacter pylori infection documented by endoscopic biopsy
Knigge K, Fennerty M, Faigel D, Magaret N, Marquis S, Vartan G, Laine L. An office-based whole blood test is preferable to a laboratory quantitative serology test in the determination of Helicobacter pylori infection documented by endoscopic biopsy. Gastroenterology 1998, 114: a180. DOI: 10.1016/s0016-5085(98)80731-2.Peer-Reviewed Original ResearchHelicobacter pylori infectionWhole blood testEndoscopic biopsyBlood testsPylori infectionSerology tests
1996
The influence of size or number of biopsies on rapid urease test results: a prospective evaluation
Laine L, Chun D, Stein C, El-Beblawi I, Sharma V, Chandrasoma P. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation. Gastrointestinal Endoscopy 1996, 43: 49-53. PMID: 8903818, DOI: 10.1016/s0016-5107(96)70260-2.Peer-Reviewed Original ResearchConceptsRegular biopsiesPositive testJumbo biopsyForceps biopsyAmount of tissueRapid urease test resultsHelicobacter pylori infectionNumber of biopsiesRapid urease testingUrease test resultsValuable diagnostic toolEndoscopic biopsyProspective evaluationPylori infectionUrease testingDiagnostic yieldHistologic examinationUrease testBiopsyRapid ureasePatientsFalse negative rateDiagnostic testsInterobserver agreementMean time